Close Menu

A new Massachusetts-based startup company called Noblegen is trying to make a simpler version of nanopore genome sequencing technology, with the hope of making it cheap and fast enough for widespread use in clinical labs, reports Technology Review's Katherine Bourzac. The company's CEO Frank Feist says Noblegen's goal is to sequence at a rate of 50 base pairs per second, and that the technology could be scaled up to sequence about 30 genomes in 15 minutes, Bourzac adds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.